Full text is available at the source.
Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients
Possible benefits of GLP-1 receptor drugs for heart failure with normal pumping in obese patients
AI simplified
Abstract
GLP-1 receptor agonists semaglutide and tirzepatide may reduce body weight by 13.3% and 13.9%, respectively, in individuals with heart failure and obesity.
- GLP-1 receptor agonists are associated with significant increases in exercise capacity, with improvements of 21.5m and 26m in 6-minute walk distance.
- Quality of life improvements were noted, with increases of 19.5 and 16.6 points in Kansas City Cardiomyopathy Questionnaire scores.
- Both medications led to substantial reductions in systemic inflammation, evidenced by decreases in C-reactive protein levels of 38.8% and 43.5%.
- Current evidence is limited due to short trial durations and a lack of population diversity.
- Further research is needed to assess long-term safety and efficacy, including hospitalization rates and cardiovascular events.
AI simplified